Muscle Pharm Corporation (MSLPQ)

[TheExpertHimself]

Quote from Musclepharm's shareholders' letter in 2013:

"Over the past three years we achieved exponential product sales growth, growing from around $1.4 million in revenue for 2009, to approximately $78 million in 2012. However, to finance that growth from essentially a startup mode we had to utilize dilutive financing instruments, which were very expensive and hurt our financial performance, and as one would expect, our stock price suffered too. All of us at MusclePharm believe that our market capitalization today is not a valid reflection of our Company's current underlying fundamentals.."

sounds like Brad doesn't like dilution much..kind of encouraging after so much in 2014...